Point72 DIFC Ltd purchased a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 8,992 shares of the company’s stock, valued at approximately $124,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. NEOS Investment Management LLC bought a new stake in Day One Biopharmaceuticals in the fourth quarter worth about $226,000. Superstring Capital Management LP bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $5,543,000. Braidwell LP lifted its stake in Day One Biopharmaceuticals by 13.5% during the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after purchasing an additional 500,000 shares during the last quarter. Parkman Healthcare Partners LLC boosted its holdings in Day One Biopharmaceuticals by 34.2% during the fourth quarter. Parkman Healthcare Partners LLC now owns 625,749 shares of the company’s stock worth $9,136,000 after buying an additional 159,341 shares in the last quarter. Finally, Quintet Private Bank Europe S.A. grew its position in Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after buying an additional 1,000 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.
Analyst Upgrades and Downgrades
DAWN has been the subject of several research reports. JPMorgan Chase & Co. reduced their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Piper Sandler reissued an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, July 30th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, August 1st. Finally, Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $35.71.
Insider Buying and Selling at Day One Biopharmaceuticals
In other news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the transaction, the insider now directly owns 1,097,535 shares of the company’s stock, valued at approximately $15,606,947.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Adam Dubow sold 3,202 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the sale, the general counsel now directly owns 26,928 shares of the company’s stock, valued at approximately $376,992. The disclosure for this sale can be found here. Insiders sold 68,748 shares of company stock worth $1,009,272 over the last ninety days. 8.40% of the stock is currently owned by insiders.
Day One Biopharmaceuticals Stock Performance
Day One Biopharmaceuticals stock opened at $14.00 on Wednesday. The firm’s 50 day moving average price is $14.08 and its two-hundred day moving average price is $14.48. The firm has a market cap of $1.22 billion, a PE ratio of -5.58 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $18.07.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last issued its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.70. The firm had revenue of $8.19 million during the quarter, compared to analyst estimates of $0.90 million. Equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current fiscal year.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Stories
- Five stocks we like better than Day One Biopharmaceuticals
- What is the Dogs of the Dow Strategy? Overview and Examples
- Ready for Growth? Barrick Gold Stock Could Be the Answer
- What is the NASDAQ Stock Exchange?
- Trade Like a Member of Congress With These 2 ETFs
- Roth IRA Calculator: Calculate Your Potential Returns
- October’s Top 3 Stocks Revealed by MarketBeat’s MarketRank Tool
Want to see what other hedge funds are holding DAWN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report).
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.